

USEPA/ORD Computational Toxicology Workshop Research Triangle Park, NC Sept. 29 - 30, 2003

Raymond W. Tennant, Ph.D.

Director, National Center for Toxicogenomics


National Institute of Environmental Health

Sciences





Toxicogenomics







Why have an NCT?

The rapid development of genomic technologies provides an unprecedented opportunity to address highly intractable problems of toxicology and environmental health.

- The value of surrogate models for prediction of human health risk
- Identify biomarkers of incipient adverse effects
- Harness the results of diverse research efforts for the collective benefit
- Provide a rational basis for risk assessment
- Facilitate the identification of specific susceptibility polymorphisms and relate them to environmental diseases



"...research conducted by the intramural program...has to be second to none and should fulfill a unique mission. It should do those things that are truly inaccessible to extramural institutions, things the nation needs done that neither industry nor academia can do."

Elias Zerhouni

Director, NIH, 2003



Road Map for the Development of Toxicogenomics

Three Objectives

- Discovery toxicology identifying and understanding mechanisms of toxicity
- Identification of biomarkers of toxicity
- Information base development



Discovery toxicology

- global gene/protein expression-enhanced identification of mechanisms of adverse effects
- studies conducted on individual events/processes



Road Map for the Development of Toxicogenomics

Three Objectives


- Discovery toxicology identifying and understanding mechanisms of toxicity
- Identification of biomarkers of toxicity
- Information base development



- Identification of biomarkers of toxicity
 - linkage of altered gene expression patterns to specific adverse effects – "phenotypic anchoring"
 - query of gene patterns from multiple agents and effects



Image Analysis and Data Acquisition



•Outlier Detection

Processing

- Validation
- Transformation
- Standardization

Multivariate Analyses

- •PCA
- Clustering
- Partitioning
- •Discriminant Analysis
- •SOM

Eigenvalues


Tree Nodes

K-dimensions


Classifications

Neural Networks

Gene Expression Pattern




Toxicity information



Integration of Diverse Data



Biomarker Identification Model Based Approach





Steps to Validate the Toxicogenomic Approach

- Determine whether gene expression profiles will allow discrimination of compound class
- Test the ability to predict unknowns



Hamadeh, HK, Bushel, PR, Jayadev, S, Martin, K, DiSorbo, O, Sieber, S, Bennett, L, Tennant, RW, Stoll, R, Barrett, JC, Blanchard, K, Paules, RS, and Afshari, CA. (2002) Gene expression analysis reveals chemical-specific profiles. *Toxicological Sciences* 67(2): 219-231.

Hamadeh, HK, Bushel, PR, Jayadev, S, DiSorbo, O, Bennett, L, Li, L, Tennant, R, Stoll, R, Barrett, JC, Paules, RS, Blanchard, K, and Afshari, CA. (2002) Prediction of compound signature using high density gene expression profiling. *Toxicological Sciences* 67(2): 232-240.



Strategy for Phenotypic Anchoring

- Profile specific important organ toxicities
- Use multiple compounds that elicit that particular toxicity
- Use toxic and subtoxic doses and times
- Use nontoxic isomers or related compounds if available
- Profile early steps in disease processes
- Perform analyses at multiple times following exposures




Hamadeh, H.K., Knight, B.L., Haugen, A.C., Sieber, S., Amin, R.P., Bushel, P.R., Stoll, R., Blanchard, K., Jayadev, S., Tennant, R.W., Cunningham, M.L., Afshari, C.A. and Paules, R.S. (2002)

Methapyrilene toxicity: Anchorage of pathological observations to gene expression alterations.

Toxicologic Pathology 30 (4): 470-482.



Integration of Gene Expression Data





A Strategy for Toxicogenomics

Short-term Goals

Predictive Assays

- Signature patterns of exposure
- Signature patterns of adverse effects
- Proteomic analysis
- Biomarker identification

Long-term Goals

Information Base

- Gene expression database
- Analysis tools (informatics)
- Query tools
- Relational interfaces and annotation



Road Map for the Development of Toxicogenomics

Three Objectives

- Discovery toxicology identifying and understanding mechanisms of toxicity
- Identification of biomarkers of toxicity
- Information base development



What are the Goals of CEBS?

Develop a high quality public knowledge base

- Create a reference toxicogenomic information system of studies on environmental chemicals/stressors and their effects (a public resource for the scientific community).
- Develop relational and descriptive data compendia on toxicologically important genes, groups of genes, SNPs, mutants, and biological phenotypes that are relevant to human health and environmental disease.
- Support hypothesis-driven and discovery research in environmental toxicology - and the research needs of risk assessment.



- Information base development
 - Chemical Effects in Biological Systems (CEBS)

Phases

Data Validity

Data Aggregation

Analysis and Query



Data Validity

Develop standards for data quality




MGED Society Standards

Microarray Gene Expression Data Society (1999)

EBI + major academics + companies in microarray, e.g.

TIGR	Stanford University	lobion
NCBI	Sanger Centre	Affymetrix
DDBJ	University of California	Agilent / Rosetta

MGED Working Groups





MIAME/Tox

- Define the core data common to most experiments
 - Minimum/sufficient information
 - Structured information
- MIAME/Tox is based on MIAME
 - Reaffirms the use of MAGE-OM and MAGE-ML standard for data model and exchange format
 - Encourages the use of the MGED Ontology for experiment annotation
 - Supports MGED standard for recording controls and normalization methods
- MIAME/Tox focuses on tox-specific metadata
 - Sample treatments and associated outcomes



Data Aggregation

Provide global access via and Oracle database

Seek partners to populate with high quality data

multi-genome

multi-agent

multi- effect



Gaining Content for CEBS

Intramural and Extramural Partnerships

Toxicogenomics
Research Consortium

DU, MIT, OHSU, UNC, FHCC-UWA &

NIEHS Microarray Group

Microarray and Proteomics Groups, Tox/Path Team, Database Group

External Partnerships EBI, NCICB, ILSI

Data Sharing MAGE-ML



Chemical Effects in Biological Systems (CEBS) Knowledge Base



National Toxicology Program



International Partners





Toxicogenomics



NIH National Center for Toxicogenomics (NCT)

and

National Toxicology
Program

EMBL-European


Bioinformatics Institute (EBI)


and

International Life
Sciences Institute (ILSI)
Health and Environmental
Sciences Institute (HESI)



CEBS Infrastructure






Aiding in development of new algorithms and computational tools that allow predictive modeling of gene interactions

including protein arrays and SNP arrays.

Internet





- Information base development
 - Chemical Effects in Biological Systems (CEBS)

Phases

Data Validity

Data Aggregation

Analysis and Query



Toxicology/Pathology Pathways

- Capture Domain Knowledge as Toxicology-Pathology-Specific Pathways
- Pathway Representation
 - BioCarta 320 Pathways currently in CEBS
 - KEGG 155 Pathways
 - GenMAPP 50 Pathways
 - -e.g., inflammation
- Creation of a Domain Expert Infrastructure
 - Web site for Pathway Annotation/Updating
 - Committee for Vetting of Annotations/Updates



Implications of Toxicogenomics for Safety and Risk Assessments – The Why

We rely on simplified assays and models that underestimate the biological complexity underlying toxic effects.

Our current safety and risk assessments are replete with untested, and often unstable, assumptions.

The interfacing of genomics technologies with toxicology provides the most profound way to truly investigate the biological complexity and to create a "Systems Toxicology."



Implications of Toxicogenomics for Safety and Risk Assessments – The What

The capability to observe the dose-rate effects of individual toxicants on the trans-genomic pattern of gene expression provides a capability to understand the full biological complexity underlying adverse effects.

What specific issues in risk assessment can toxicogenomics address?



Specific Issues in Safety and Risk Assessment that can be Addressed by Toxicogenomics

- Provide the capability to identify <u>new</u> mechanisms, pathways, and biomarkers of toxicity.
- Provide the capability to directly assess the relevance of surrogate models for predicting human risk.
- Provide the capability to relate specific susceptibility factors to environmental disease risk.
- Provide the capability to compile data on many potential toxicants, adverse effects, susceptibility factors, etc. in many biological systems and to search for previously unrecognized associations that can lead to new hypotheses of toxicity.
- Provide the capability to understand toxicity and to be able to predict incipient toxicity.



Conclusions

- Genome-based technologies provide an unprecedented opportunity to explore the biological complexity underlying adverse effects.
- > The opportunities are no greater than the challenges of being able to explore high density data.
- Progress will occur slowly and incrementally; a solid foundation for high quality data assimilation and analysis must be established.
- The opportunity now exists for creating an information base which compiles the results of diverse individual studies into a compendium of chemical effects in biological systems that can be a resource for the scientific community.

9/29/2003



The Unknown

As we know,

There are known knowns.

There are things we know we know.

We also know

There are known unknowns.

That is to say

We know there are some things

We do not know.

But there are also unknown unknowns,

The ones we don't know we don't know.

Donald H. Rumsfeld

February 12, 2002, Department of Defense news briefing



Acknowledgements

Rick Paules
Jeff Tucker

Microarray Team

Pierre Bushel

Bioinformatics Team

Gary Boorman Rick Irwin Mike Cunningham

ToxPath Team

Alex Merrick Ken Tomer **Proteomics Team**

Mike Waters Jim Selkirk **CEBS Team**

Brenda Weis Ben Van Houten

Toxicogenomics Research Consortium Team

Stan Stasiewicz

NCT Resource Contract Management